Utilization of the Fibroscan® in Community Based Clinics

Anna Marie Hefner, PhD, CPNP1,2, Renee Pozza, PhD, RNP-BC1,2, Tarek I. Hassanein, MD1; 1. Southern California GI & Liver Centers, Coronado, CA; 2. Azusa Pacific University, Azusa, CA.

BACKGROUND

FibroScan® has become a mechanism to establish the presence of fibrosis or cirrhosis in patients with chronic liver diseases. It is important to identify the assessment of prognosis and for evidence of the progression of disease in disorders such as hepatitis C virus (HCV) infection, fatty liver disease (NAFLD/NASH), hepatitis B virus (HBV) infection, and co-infection of human immunodeficiency virus (HIV) and HCV.

FibroScan® measures the stiffness (fibrosis) based on the velocity of transmission of a shear wave through the liver, created by a vibratory source. Currently, this technique has been used most consistently in patients with chronic HCV.

Though the liver biopsy has been the “gold” standard to stage liver fibrosis, it remains an invasive test and samples only a very small piece of the liver.

METHODS

Descriptive Retrospective Study
Patients were referred for a Fibroscan® if diagnosed with chronic liver disease
Identification of liver disease was recorded
Scan was performed and result sent to the referring physician/organization.
Patient received the results at the time of the testing

RESULTS

<table>
<thead>
<tr>
<th>Sex</th>
<th>Male-1097 (55%)</th>
<th>Female- 889 (45%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baby Boomers</td>
<td>Yes-735 (67%)</td>
<td>No-579 (65%)</td>
</tr>
</tbody>
</table>

Table 1. Demographics of Population

SUMMARY

The use of fibroscan in the community setting allows for the staging of fibrosis in patients with chronic liver disease.

The clinician has instantaneous results to assist in making decisions during the patient’s visit.

With the CDC recommendations of screening all Baby Boomers for HCV and the anticipated increase in the diagnosis of HCV in this age group, the fibroscan is both an economical method of staging of fibrosis and non-invasive.

As additional studies are conducted, the establishment of this technique will continue to evaluate hepatic fibrosis in patients with chronic liver disease.

CONCLUSIONS

The availability of non-invasive and affordable diagnostic methods for fibrosis allowed an increase liver disease staging.

The data underscores the importance of staging patients with chronic liver irrespective to age group.

Given a choice, the patients prefer FibroScan® over liver biopsy.

For more information, please contact
Dr. Anna Marie Hefner
ahefner@livercenters.com
livercenters.com

Table 1. Demographics of Population

Fibrosis Stage by Age Group

Fibrosis Stage by Baby Boomers

For more information, please contact
Dr. Anna Marie Hefner
ahefner@livercenters.com
livercenters.com